{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:47:05Z","timestamp":1790254025895,"version":"4.1.0"},"reference-count":51,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T00:00:00Z","timestamp":1368489600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0062104","type":"journal-article","created":{"date-parts":[[2013,5,14]],"date-time":"2013-05-14T21:06:09Z","timestamp":1368565569000},"page":"e62104","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":29,"title":["mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF"],"prefix":"10.1371","volume":"8","author":[{"given":"Daisuke","family":"Ishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Nanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Ebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Yasumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,5,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"TJ Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"JG Paez","year":"2004","journal-title":"Science"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"W Pao","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"D Jackman","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"W Pao","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"S Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domein","volume":"2","author":"W Pao","year":"2005","journal-title":"PLoS Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"JA Engelman","year":"2007","journal-title":"Science"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"AB Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutation","volume":"68","author":"S Yano","year":"2008","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.lungcan.2011.01.008","article-title":"Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma","volume":"73","author":"H Uramoto","year":"2011","journal-title":"Lung Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMc053610","article-title":"EGFR mutations in small-cell lung cancers in patients who have never smoked","volume":"355","author":"MF Zakowski","year":"2006","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.lungcan.2007.05.014","article-title":"Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation","volume":"58","author":"R Morinaga","year":"2007","journal-title":"Lung Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1158\/1078-0432.CCR-08-0332","article-title":"Epidermal growth factor receptor mutations in small cell lung cancer","volume":"14","author":"TH Shiao","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1158\/1535-7163.MCT-07-0138","article-title":"Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma","volume":"6","author":"BA Frederick","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref16","first-page":"2513","article-title":"Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma","volume":"30","author":"H Uramoto","year":"2010","journal-title":"Anticancer Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1097\/JTO.0b013e318216ee52","article-title":"Maehara Y, Yatabe Y, Sekido Y, Mitsudomi T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib","volume":"6","author":"K Suda","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"TG Bivona","year":"2011","journal-title":"Nature"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nm.2577","article-title":"EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers","volume":"18","author":"M Garofalo","year":"2011","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Z Zhang","year":"2012","journal-title":"Nat Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/JTO.0b013e31823ab0dd","article-title":"Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort","volume":"6","author":"S Yano","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1158\/1078-0432.CCR-09-1001","article-title":"Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"15","author":"W Wang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-11-1171","article-title":"Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer","volume":"18","author":"W Wang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ajpath.2012.05.023","article-title":"Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer","volume":"181","author":"S Takeuchi","year":"2012","journal-title":"Am J Pathol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1158\/1535-7163.MCT-12-0195","article-title":"Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer","volume":"11","author":"T Nakagawa","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-10-1993","article-title":"Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer","volume":"17","author":"IS Donev","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR signalling pathway in human cancer","volume":"13","author":"P Helena","year":"2012","journal-title":"Int J Mol Sci"},{"key":"ref28","first-page":"4","article-title":"Antiangiogenesis therapy: a new strategy for cancer treatment","volume":"35","author":"F Xiaodong","year":"2010","journal-title":"US Pharm"},{"key":"ref29","first-page":"51","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"K Jayashree","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"ref30","first-page":"1491","article-title":"Regulation of hypoxia-inducible factor 1: expression and function by the mammalian target of rapamycin","volume":"11","author":"CC Hudson","year":"2003","journal-title":"Mol Cell"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1083\/jcb.129.5.1411","article-title":"Hepatocyte growth factor\/scatter factor modulates cell motility, proliferation, and proteoglycan synthesis of chondrocytes","volume":"129","author":"T Takebayashi","year":"1995","journal-title":"J Cell Biol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1349-7006.2012.02279.x","article-title":"Ligand-triggered resistance to molecular targeted drugs in lung cancer: Roles of hepatocyte growth factor and epidermal growth factor receptor ligands","volume":"103","author":"S Yano","year":"2012","journal-title":"Cancer Sci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1078-0432.CCR-09-1204","article-title":"Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer","volume":"16","author":"T Yamada","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1470-2045(11)70129-2","article-title":"EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications","volume":"2012;13","author":"H Yasuda","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"AB Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-11-2972","article-title":"Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells","volume":"18","author":"T Yamada","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"R Straussman","year":"2012","journal-title":"Nature"},{"key":"ref38","first-page":"629","article-title":"PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients","volume":"1","author":"H Endoh","year":"2006","journal-title":"J Thorac Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00428-012-1239-6","article-title":"Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer","volume":"460","author":"MH Oh","year":"2012","journal-title":"Virchows Arch"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-10-1993","article-title":"Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer","volume":"17","author":"IS Donev","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.tibs.2008.08.002","article-title":"HIF-1 regulation: not so easy come, easy go","volume":"33","author":"M Yee Koh","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/1947601912445376","article-title":"Regulation of PI 3-K, PTEN, p53, and mTOR in malignant and benign tumors deficient in tuberin","volume":"2","author":"LH Samy","year":"2011","journal-title":"Genes Cancer"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"16309","DOI":"10.1074\/jbc.M710079200","article-title":"Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism","volume":"283","author":"RM Young","year":"2008","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1200\/JCO.2003.10.038","article-title":"Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial)","volume":"21","author":"M Fukuoka","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"TS Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31825581bd","article-title":"The mTOR pathway in lung cancer and implications for therapy and biomarker analysis","volume":"7","author":"S Ekman","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/JTO.0b013e31824de0d6","article-title":"Brief report: a phase II \u201cwindow-of-opportunity\u201d frontline study of the mTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study","volume":"7","author":"T Reungwetwattana","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref48","first-page":"1623","article-title":"Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer","volume":"1","author":"KA Price","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1200\/jco.2010.28.15_suppl.7524","article-title":"Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)","volume":"28","author":"NB Leighl","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/JTO.0b013e3182614835","article-title":"Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"VA Papadimitrakopoulou","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-012-1946-3","article-title":"Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"70","author":"S Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0062104","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T09:42:43Z","timestamp":1589017363000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0062104"}},"subtitle":[],"editor":[{"given":"Jung Weon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,5,14]]},"references-count":51,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0062104","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,14]]}}}